Startup making software for pharma manufacturing industry nets $12M+ Series A

Ganymede Bio CEO and co-founder Nathan Clark claims software for biotechs is 10 to 20 years behind other industries. His company just received $12.75 million to provide drugmakers with more options.

Ganymede Bio is a cloud infrastructure provider targeting the life science and pharma manufacturing industries. The startup, which was only founded this year, unveiled its Series A round on Tuesday. Combined with an earlier seed round, the company has raised a total of $15.6 million as it works to secure more clients in the manufacturing and biopharma space.

Nathan Clark

Clark told Endpoints News that Ganymede seeks to integrate hardware in laboratories or manufacturing sites, such as equipment or instruments, and applications into one platform that’s managed by the biotech or manufacturer.

“I think there’s a lot of companies that offer lab integration and instrument integration is sort of a service. And they have some product pieces of it like they’ll make a data lake out of what they get, but no one has actually productized building integrations themselves, and that’s been a really effective paradigm for us,” he said.

The Series A funds will be used for hiring and maintaining Ganymede’s staff of software engineers, he said. In the near future, the company aims to add more features and work with lab instrument manufacturers on better ways to connect data. The team’s also focused on netting more partnerships and getting more companies onto the platform.

“The same way as if you were to start a consumer finance app or something in 2022, you would go get AWS setup and build out all your tech on there. We want Ganymede to be the go-to place to say ‘Hey, I’m starting a biotech company. I gotta go get Ganymede, and set up my stuff in there, and connect all my lab instruments in there,’” he said.

Ganymede has worked with Apprentice, another tech company, on some automation efforts for manufacturers, Clark said. In 2023, he hopes to build out Ganymede’s client list.

“We’re working with Apprentice, some (clients) that are actually manufacturing drugs, others who are manufacturing the components…We’re actively also looking to expand into that ourselves more directly and start getting some of our own direct large pharma clients. Our client base today is pretty heavily focused on mid- to late-stage biotechs, I would say in their scientific labs, so we’re looking to kind of bring this to the broader market,” Clark said.

The Series A round was led by Caffeinated Capital.

manufacturing
biotech
pharma
instrument
hardware